As we at Yaohai Bio-Pharma look toward 2026, the landscape of biologics formulation development is poised for significant innovation and efficiency improvements. With rapid advances in
Optimizing downstream process development is a critical step to ensure the production of high-quality biologics, especially in the context of increasing complexity of modern protein therapeutics.
Pharmaceutical development has evolved significantly over the years, and at Yaohai Bio-Pharma, we have witnessed and contributed to this transformation. The shift in pharmaceutical formulation
At Yaohai Bio-Pharma, we have extensive experience in vaccine manufacturing, particularly focusing on microbial-based systems. Live attenuated vaccines have long been recognized for their ability
Developing and producing vaccines efficiently requires careful planning, advanced technology, and specialized expertise. At Yaohai Bio-Pharma, we understand the challenges that biotech companies face when
The rapid emergence of mRNA technology has revolutionized vaccine development and the way we approach immunization. At Yaohai Bio-Pharma, we are deeply engaged in the
Antibody fragments have become essential tools in modern therapeutic research, offering smaller size, higher tissue penetration, and improved stability compared to full-length antibodies. At Yaohai
In modern therapeutic development, many antibody programs start with an ScFv fragment due to its flexibility and historical usage. However, as projects progress toward clinical application,
Outsourcing vhh antibody production has become a practical choice for biotech companies seeking efficiency, regulatory alignment, and scalable development pathways. As nanobody-based therapeutics continue to
In recent years, the research landscape around vhh single domain antibody technologies has broadened rapidly, reflecting their versatile biological traits. At Yaohai Bio-Pharma, we see a
